# CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

> **NCT06839976** · PHASE1,PHASE2 · RECRUITING · sponsor: **Children's Hospital of Philadelphia** · enrollment: 24 (estimated)

## Conditions studied

- SLE
- Systemic Lupus Erythematosus (SLE)
- CAR T Cell
- CART19
- Cell Therapy
- Lupus
- Lupus Nephritis (LN)

## Interventions

- **BIOLOGICAL:** CART19

## Key facts

- **NCT ID:** NCT06839976
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-06
- **Primary completion:** 2030-02-28
- **Final completion:** 2030-02-28
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06839976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06839976, "CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06839976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*